MET and cancer: The gene coding for c-Met is considered a protooncogene because abnormal activation of c-Met can promote the development and progression of multiple cancers, such as liver, lung, colon, breast, pancreatic, ovarian, prostate, and gastric carcinomas, in addition to cancers of the nervous system, such as glioblastoma [58–60].